Acartus

Acartus was a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare lysosomal storage disorders, specifically Gaucher disease. The company's lead program, AC-1101, was a small molecule substrate reduction therapy (SRT) designed to inhibit glucosylceramide synthase and prevent the toxic accumulation of lipids. By targeting the underlying metabolic pathway, Acartus aimed to provide a more effective oral treatment option for patients with Gaucher disease types 1, 2, and 3. In 2018, the company's assets and intellectual property were acquired by Centogene to bolster their rare disease therapeutic pipeline.